Navigation Links
COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results
Date:8/3/2009

WOODBURY, N.Y., Aug. 3 /PRNewswire-FirstCall/ -- COMFORCE Corporation (NYSE Amex: CFS), a leading provider of outsourced staffing management services, specialty staffing and consulting services, today announced that it will report its second quarter 2009 results on Wednesday, August 5, 2009 prior to market opening.

COMFORCE will sponsor a conference call on Wednesday, August 5, 2009 at 2 P.M. Eastern Time, hosted by John Fanning, Chairman and Chief Executive Officer, Harry Maccarrone, Executive Vice President and Chief Financial Officer, and Bob Ende, Senior Vice President-Finance. The purpose of the call is to discuss COMFORCE's second quarter 2009 results.

The call will be broadcast live over the Internet via www.earnings.com. For those who are unavailable to listen to the live broadcast, a replay will be available shortly after the call on the above web site for 90 days.

About COMFORCE

COMFORCE Corporation is a leading provider of outsourced staffing management services that enable Fortune 1000 companies and other large employers to consolidate, automate and manage staffing, compliance and oversight processes for their contingent workforces. We also provide specialty staffing, consulting and other outsourcing services to Fortune 1000 companies and other large employers for their healthcare support, technical and engineering, information technology, telecommunications and other staffing needs. We operate in three segments -- Human Capital Management Services, Staff Augmentation and Financial Outsourcing Services. The Human Capital Management Services segment provides consulting services for managing the contingent workforce through its PRO(R) Unlimited subsidiary. The Staff Augmentation segment provides Heal
'/>"/>

SOURCE COMFORCE Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2Health News:Oklahoma Students Win Be Smart-Don't Start! Contest 2Health News:Consumer Watchdog Raises Concern That Health Policy Cancellation Rules Have Been Derailed in Deal With Kaiser 2Health News:Consumer Watchdog Raises Concern That Health Policy Cancellation Rules Have Been Derailed in Deal With Kaiser 3Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:US Companies Aid Chinese Earthquake Victims 2Health News:US Companies Aid Chinese Earthquake Victims 3Health News:US Companies Aid Chinese Earthquake Victims 4Health News:US Companies Aid Chinese Earthquake Victims 5Health News:US Companies Aid Chinese Earthquake Victims 6Health News:US Companies Aid Chinese Earthquake Victims 7
Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Simulation helps students learn dental implant procedures 48631 1Simulation helps students learn dental implant procedures 48631 2Simulation helps students learn dental implant procedures 48631 3U S Drug Czar Addresses 2 500 Drug Court Professionals Voices Strong Support for Expanding Drug Courts Throughout the Nation 48628 1U S Drug Czar Addresses 2 500 Drug Court Professionals Voices Strong Support for Expanding Drug Courts Throughout the Nation 48628 2U S Drug Czar Addresses 2 500 Drug Court Professionals Voices Strong Support for Expanding Drug Courts Throughout the Nation 48628 3Are angiotensins involved in the hemodynamic changes of cirrhosis patients 3F 48625 1Are angiotensins involved in the hemodynamic changes of cirrhosis patients 3F 48625 2